Its a lie no volume near that - and with breast cancer data that just came out this will be loser
This is the moron that told us to short CELG at $40 presplit so $20 in todays term to $112...Good call. The only better contra indicator for a certain CELG run to new highs than this dumb shlt is
when ortigia60 show up...
Griffin you can be sure is getting this from RJ Kirk...this is as close to direct words out of RJ's mouth as you can get....Maybe for other companies yes - but for XON and ZIOP Chrystyna of Griffin is RJ's right hand person and you can be sure the facts are getting to Keith. Trust that this report is from a direct line from RJ., It also closely resembles what RJ said publicly on the Q3 call last week. A deal is clearly coming and I say it triples ZIOP
CELG will take AGIO out early next yr - will hit $100 by yr end and CELG takes out for $140 in 2015. Amazing this company has 3 drugs with data ALL WORKING in 2 mutations and they could go to 10 mutations in 50 inidications.
CELG owns 50% by mid-2015 they will own 100% of AGIO - it fits like a glove.
Thanks for posting JP Morgan and Jeffries and JMP are good biotech analysis firms - this stock is clearly undervalued
Wrong this is the way to go - EU has antipsychotic problem also - they will approval - its the ex-CHMP approvers who recommended this. GREAT NEWS
EPS growth at a 60% discount of one of the best run companies with the best pipelines in biotech - deeply undervalued. Buy CELG and put in draw for 3 yrs - triple coming.
CELG is deeply undervalued - they have the upper hand in patent case - and now Aspire ensures duration increases - Up to $32 INCREMENTAL price appreciation not in $115 target. Love this comment:
"From our model with duration increases similar to Aspire in the US ONLY AND pipeline, we think that the co could potentially be worth $128-$174/share.--Reiterate Buy and $115 TP. We believe that Celgene has one of the most transformational internal & external pipelines in biotech"
I think this will push CELG and AMGN to all time highs....Celgene run will be over multiple days...grab some trading shares - really
Ortigia60 is an amazing contr-indicator - he has been telling you to sell since the 50s - dissappeared on the triple - then suddenly posted like a madman again when we sunk with biotechs and told you to short in the 140s...now in the 170 area he is gone again. Amazing.
Disagree - insiders of course need to sell some for financial planning purposes - dont want your job and AL net worth in one company - just prudent and done with a 10b5-1 plan - its fine - and they still own huge amounts...they deserve every penny.
This is a 60 dollar stock in 12 to 18 months and I am adding and liking the dip
For long term holders this secondary allows you to keep this for yrs and not look at day to day sector related moves....I know ACAD will make me rich in a few yrs - doesn't matter its down with sector now - the secondary makes me sure there will be no dilution until after approval - couldn't think of a better place to have my investment money
Ridiculous that the slow growing pharmas have higher PE's than high growth biotech. Can't last. When the biotech sector reverses -and it will soon - CELG will gain $15 quickly, When the Markman case reads out - it will go to 180. CEO was very confident on Squawk Box yesterday. Earnings will be good based on his comments. I cant think of a better place for my money
Yes Otezla approval likely this week latest next week, AnkSpond 2.5 million patients Ph 3 data also coming soon. New highs coming
Piper raising ACAD target from $28 to $42 - Pipeline Progress Should Enhance Conviction in PDP This Year
COMPANY NOTE PIPER JAFFRAY March 7, 2014
ACADIA Pharmaceuticals (ACAD) Overweight
ACADIA recently reported 4Q13 results and provided pipeline updates, as well as completed an equity raise netting ~$197mn. Guidance for a "near YE" NDA filing for pimavanserin (pima') in PDP remain intact. Management indicated NDA preparatory activities, stability testing and drug-drug interaction studies are progressing well, and we believe these timelines may accelerate. ACADIA ended the year with $186mn. With the recent raise and despite anticipated expenses for establishing a US commercial infrastructure, we see current cash as sufficient to fund to profitability, contingent on our revenue projections being met.
• ADP thoughts. The company is constructive on the conduct of the Alzheimer's dependent psychosis (ADP) Phase II study, however, will not provide enrollment updates (we suspect it may be ahead of schedule given the trial design and patientcohort). Based on our diligence on pima’s potential beyond PDP, we are moving to a DCF-based valuation (Exhibit 1 vs. prior sales multiple in Exhibit 2) of the PDP and ADP indications to better capture ACADIA's intrinsic value, resulting in an increase of price target to $42 from $28, while use in schizophrenia remains as upside to our model.
• Measured progress. ACADIA provided updates to the pima' clinical program, with everything conservatively remaining on track to previously guided timelines. That said, we have enhanced conviction on the ability of this team to execute as a result of recent hiring of management with commercial experience. As a result of ongoing diligence on pima’ and the ADP study design, we are increasingly optimistic for the
prospects in ADP, the company outlined some of the advantages
Since $60 you have been shorting every single pop - the counter indictor that will make you rich. Do the opposite of wrong way ortigia